Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Home Depot Inc (HD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Home Depot Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.01 (market cap $29.60B), while Home Depot Inc trades at $344.19 (market cap $353.46B). The key difference: Home Depot Inc is far larger — about 11.9× Alnylam Pharmaceuticals, Inc.'s market cap, and Home Depot Inc pays a 2.63% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | HD | |
|---|---|---|
Market Cap | $29.60B | $353.46B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $423.42 |
52-Week Low | $205.48 | $297.51 |
Enterprise Value | $27.56B | $415.01B |
Dividend Yield | — | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Home Depot (HD) trades at $354.48, up 1.05% for the day, with a bullish technical signal from moving averages and a consensus analyst price target of $371.25. The company reported revenue of $159.51B in 2025, with a net income margin of 8.41%, though recent earnings showed a mix of beats and a miss. Institutional activity is mixed, with some firms increasing and others decreasing holdings.
The outlook remains positive with analyst buy ratings at 59%, but risks include weakening big-ticket demand and margin pressures. Upside potential exists from Pro customer growth and housing tailwinds, but investors should monitor competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →
